Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 10,084 Shares

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 10,084 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $595,460.20. Following the transaction, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at approximately $5,973,852.30. This represents a 9.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

James William Rogers also recently made the following trade(s):

• On Thursday, December 11th, James William Rogers sold 19,966 shares of Tempus AI stock. The stock was sold at an average price of $73.20, for a total value of $1,461,511.20.

Tempus AI Trading Down 2.7%

TEM traded down $1.59 during trading on Friday, hitting $58.37. 7,883,470 shares of the company’s stock were exchanged, compared to its average volume of 5,746,147. The stock has a 50 day moving average price of $62.60 and a 200 day moving average price of $73.38. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The firm has a market cap of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TEM. Cranbrook Wealth Management LLC acquired a new position in Tempus AI during the 3rd quarter worth $25,000. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the third quarter valued at about $26,000. Los Angeles Capital Management LLC bought a new position in Tempus AI during the fourth quarter valued at about $27,000. GAMMA Investing LLC bought a new stake in shares of Tempus AI during the third quarter valued at approximately $28,000. Finally, Allworth Financial LP lifted its holdings in shares of Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TEM. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Mizuho initiated coverage on shares of Tempus AI in a research report on Thursday. They issued an “outperform” rating and a $100.00 target price for the company. BTIG Research increased their price target on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Robert W. Baird assumed coverage on Tempus AI in a research note on Tuesday. They issued an “outperform” rating and a $59.00 price objective on the stock. Finally, HC Wainwright reduced their target price on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Hold” and an average target price of $85.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.